These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19233985)

  • 1. FDA approves fibrinogen concentrate product.
    Thompson CA
    Am J Health Syst Pharm; 2009 Mar; 66(5):428. PubMed ID: 19233985
    [No Abstract]   [Full Text] [Related]  

  • 2. [A case of dysfibrinogenemia complicated by hemorrhage and thrombosis].
    Ouvry PA; Vergoz D; Guenneguez H
    Phlebologie; 1985; 38(3):417-20. PubMed ID: 4059342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent VTE in a heterozygote of the fibrinogen Aα IVS4+1G>T and Aα p.Arg168Ter mutation.
    Berens C; Rühl H; Ivaškevičius V; Oldenburg J; Hertfelder HJ; Pötzsch B
    Thromb Haemost; 2016 May; 115(5):1073-5. PubMed ID: 26763372
    [No Abstract]   [Full Text] [Related]  

  • 4. Retrochorionic hematoma in congenital afibrinogenemia: resolution with fibrinogen concentrate infusions.
    Aygören-Pürsün E; Martinez Saguer I; Rusicke E; Louwen F; Geka F; Ivaskevicius V; Oldenburg J; Klingebiel T; Kreuz W
    Am J Hematol; 2007 Apr; 82(4):317-20. PubMed ID: 17034026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [On hemorrhagic syndromes due to fibrinogen deficiency].
    Capasso DA
    Pediatria (Napoli); 1967 Dec; 75(6):1002-9. PubMed ID: 4895740
    [No Abstract]   [Full Text] [Related]  

  • 6. Which is the preferred blood product for fibrinogen replacement in the bleeding patient with acquired hypofibrinogenemia-cryoprecipitate or fibrinogen concentrate?
    Cushing MM; Haas T; Karkouti K; Callum J
    Transfusion; 2020 Jun; 60 Suppl 3():S17-S23. PubMed ID: 32478877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinogen replacement therapy for congenital fibrinogen deficiency.
    Bornikova L; Peyvandi F; Allen G; Bernstein J; Manco-Johnson MJ
    J Thromb Haemost; 2011 Sep; 9(9):1687-704. PubMed ID: 21711446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding.
    Danés AF; Cuenca LG; Bueno SR; Mendarte Barrenechea L; Ronsano JBM
    Vox Sang; 2008 Apr; 94(3):221-226. PubMed ID: 18179679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathogensis of afibrinogenemic hemorrhages in amniotic fluid embolism].
    Skipetrov VP
    Vopr Okhr Materin Det; 1968 May; 13(5):71-3. PubMed ID: 5720176
    [No Abstract]   [Full Text] [Related]  

  • 10. Prophylactic administration of fibrinogen concentrate in a pregnant woman with congenital hypofibrinogenemia and a positive obstetric history of severe bleeding in previous cesarean section.
    Kaparou M; Danilatou V; Lydaki E; Stathoudakis G; Bolonaki I; Nikoloudi I; Foundouli K
    Blood Coagul Fibrinolysis; 2012 Sep; 23(6):566-8. PubMed ID: 22874742
    [No Abstract]   [Full Text] [Related]  

  • 11. Prophylactic cryoprecipitate in congenital afibrinogenemia.
    Rodriguez RC; Buchanan GR; Clanton MS
    Clin Pediatr (Phila); 1988 Nov; 27(11):543-5. PubMed ID: 3180628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observational study of fibrinogen concentrate in massive hemorrhage: evaluation of a multicenter register.
    Weiss G; Lison S; Glaser M; Herberger S; Johanning K; Strasser T; Huber T; Spannagl M; Heindl B
    Blood Coagul Fibrinolysis; 2011 Dec; 22(8):727-34. PubMed ID: 22024795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen-transmitted hepatitis; a controlled study.
    Mainwaring RL; Brueckner GG
    JAMA; 1966 Feb; 195(6):437-41. PubMed ID: 4159234
    [No Abstract]   [Full Text] [Related]  

  • 14. Post-authorization safety study of Clottafact
    Négrier C; Rothschild C; Borg JY; Lambert T; Claeyssens S; Sanhes L; Stieltjes N; Bertrand A; André MH; Sié P; Gruel Y; Tellier Z
    Vox Sang; 2016 Nov; 111(4):383-390. PubMed ID: 27583698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology, Efficacy and Safety of a Triple-Secured Fibrinogen Concentrate in Children Less than or Equal to 12 Years with Afibrinogenaemia.
    Djambas Khayat C; El Khorassani M; Aytaç S; Harroche A; Dahmane A; Pujol S; Henriet C; de Moerloose P; Bridey F
    Thromb Haemost; 2020 Jun; 120(6):957-967. PubMed ID: 32392604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Congenital afibrinogenemia with bleeding, bone cysts and antibodies to fibrinogen].
    Ra'anani P; Levi Y; Varon D; Gitel S; Martinowitz U
    Harefuah; 1991 Nov; 121(9):291-3. PubMed ID: 1800275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinogen concentrate use during major obstetric haemorrhage.
    Glover NJ; Collis RE; Collins P
    Anaesthesia; 2010 Dec; 65(12):1229-30. PubMed ID: 21182609
    [No Abstract]   [Full Text] [Related]  

  • 18. Three successful deliveries involving a woman with congenital afibrinogenaemia - conventional fibrinogen concentrate infusion vs. 'as required' fibrinogen concentrate infusion based on changes in fibrinogen clearance.
    Oda T; Itoh H; Kawai K; Oda-Kishimoto A; Kobayashi T; Doi T; Uchida T; Kanayama N
    Haemophilia; 2016 Sep; 22(5):e478-81. PubMed ID: 27481286
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetics and safety of fibrinogen concentrate.
    Manco-Johnson MJ; Dimichele D; Castaman G; Fremann S; Knaub S; Kalina U; Peyvandi F; Piseddu G; Mannucci P;
    J Thromb Haemost; 2009 Dec; 7(12):2064-9. PubMed ID: 19804533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thromboembolic events in patients with severe inherited fibrinogen deficiency.
    Rottenstreich A; Lask A; Schliamser L; Zivelin A; Seligsohn U; Kalish Y
    J Thromb Thrombolysis; 2016 Aug; 42(2):261-6. PubMed ID: 26712130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.